CPRIT AWARDS $15.5M TO ADVANCE ANTIBODY THERAPY
The Cancer Prevention and Research Institute of Texas (CPRIT) has
awarded $15.5 million in a Product Development Award to ImmunoGenesis,
Inc., to advance bispecific PD-L1/PD-L2 antibodies based on
discoveries made by the laboratory of Michael Curran, Ph.D., associate
professor of Immunology, and the ORBIT platform.